- Home
- CISO vs MYNZ Comparison
CISO vs MYNZ Comparison
Compare CISO & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISO | MYNZ |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 8.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CISO | MYNZ |
|---|---|---|
| Price | $0.44 | $1.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 623.0K | 195.9K |
| Earning Date | 11-13-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,743,266.00 | $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.30 | $0.92 |
| 52 Week High | $3.84 | $8.20 |
Technical Indicators
Market Signals| Indicator | CISO | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 35.70 | 51.06 |
| Support Level | $0.43 | $1.09 |
| Resistance Level | $0.49 | $1.35 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 23.44 | 54.93 |
Price Performance
Historical ComparisonAbout CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.